Survodutide Side Effects: Safety Signals and Warnings
Survodutide safety concerns are compound-specific. The main listed side effects are Nausea, Diarrhea, and Vomiting. The main warning signals are Investigational - not yet approved for any indication, GLP-1 class warning: potential risk of thyroid C-cell tumors, and Gastrointestinal side effects common during dose escalation.
Direct Answer
Survodutide now has a published Phase 3 obesity trial, but its treatment-regimen weight-loss result sits below approved tirzepatide and sponsor-reported retatrutide results. Its strongest differentiation remains liver and MASH biology, not the top position in pure weight-loss ranking.
- Evidence grade
- Level B
- Research status
- Phase 3
- Category
- Weight Loss & Metabolic
- Evidence context
- Weight loss research, MASLD/NASH, GLP-1/glucagon dual agonism pharmacology
Reported Side Effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Decreased appetite
- Dyspepsia
- Injection site reactions
- Elevated heart rate
Warnings
- Investigational - not yet approved for any indication
- GLP-1 class warning: potential risk of thyroid C-cell tumors
- Gastrointestinal side effects common during dose escalation
- Glucagon component may transiently increase blood glucose - monitoring recommended in diabetic patients
- Not studied in patients with severe hepatic or renal impairment
Known or Plausible Interactions
- Insulin and sulfonylureas (increased hypoglycemia risk)
- Oral medications (delayed absorption from slowed gastric emptying)
- Glucagon (exogenous glucagon for hypoglycemia rescue may have altered response)
Regulatory Context
Investigational - not approved. Phase 3 trials are ongoing for obesity and MASH; SYNCHRONIZE-1 topline obesity results were announced in April 2026. Available through clinical trials only.
Evidence Snapshot
| Evidence grade | Level B |
|---|---|
| Research status | Phase 3 |
| Best supported outcomes | Body Weight Reduction (Level B), Liver Fat Reduction (Level B), Glycemic Control (Level B), and Gastrointestinal Adverse Events (Level B) |
| Primary citation count | 4 |
| Last reviewed | 2026-08-27 |
Quick Answers
What are the side effects of Survodutide?
Survodutide safety concerns are compound-specific. The main listed side effects are Nausea, Diarrhea, and Vomiting. The main warning signals are Investigational - not yet approved for any indication, GLP-1 class warning: potential risk of thyroid C-cell tumors, and Gastrointestinal side effects common during dose escalation.
What is the evidence level for Survodutide?
Survodutide is rated Level B. Its current research status is Phase 3.
What is Survodutide best known for?
Weight loss research, MASLD/NASH, GLP-1/glucagon dual agonism pharmacology.
Where can I read the full Survodutide evidence review?
The full evidence review is available at https://examinepeptides.com/library/survodutide.
Related Guides
How to Cite This Page
ExaminePeptides. "Survodutide Side Effects: Safety Signals and Warnings." Last reviewed 2026-08-27. https://examinepeptides.com/answers/survodutide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.